Trial Profile
A Phase I Study of Single Agent Tazemetostat in Subjects With Advanced Solid Tumors and B-Cell Lymphomas With Hepatic Dysfunction
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Tazemetostat (Primary)
- Indications B-cell lymphoma; Liver cancer; Non-Hodgkin's lymphoma; Solid tumours
- Focus Adverse reactions
- 06 Feb 2020 Planned End Date changed from 1 Sep 2020 to 19 Sep 2019.
- 06 Feb 2020 Planned primary completion date changed from 1 Sep 2020 to 19 Sep 2019.
- 06 Feb 2020 Status changed from discontinued to withdrawn prior to enrolment.